Introduction {#Sec1}
============

Atrial fibrillation (AF) is the most common dysrhythmia occurring following cardiac surgery and may cause embolism or stroke, longer intensive care unit and total hospital stays, and increased health care costs \[[@CR1]--[@CR5]\]. Various guidelines \[[@CR6]--[@CR8]\] strongly recommend treatment with a β-blocker to prevent postoperative AF in patients undergoing cardiac surgery because the appearance of AF during the perioperative period increases myocardial oxygen consumption and may cause deterioration of a patient's hemodynamics. Furthermore, AF is considered a risk factor for myocardial ischemia because the shortened left ventricular diastolic time decreases coronary artery blood flow \[[@CR9]\]. In many cases, postoperative AF is transient and reverts spontaneously to sinus rhythm, but tachycardia due to prolonged AF may impair left ventricular function and cause congestive heart failure. Therefore, it is particularly important to control tachyarrhythmia during the perioperative period in cases of coronary artery bypass grafting (CABG). Landiolol hydrochloride (Ono Pharmaceutical Co, Ltd., Osaka, Japan), a highly regulated, ultrashort-acting β-blocker, was developed in Japan as a drug with a short half-life and very high β1 selectivity. It was hypothesized that the superior pharmacological profile of landiolol would enable safer use in patients in the acute phase of severe heart disease and in other clinical settings \[[@CR10]\] and would reduce the development of postoperative AF. Therefore, we performed a retrospective, single-institution study to determine if intraoperative administration of landiolol reduces the incidence of AF after cardiac surgery.

Methods {#Sec2}
=======

We reviewed the records of 250 consecutive patients who underwent CABG surgery between January 2011 and November 2013 at our institution. Patients with previous permanent or persistent AF or a permanent pacemaker were excluded from the analysis. One hundred and sixteen patients met these criteria. Landiolol was administered to 41 patients from January 2011 to November 2013 (group L), and this group of patients was compared with a control group of 75 patients who were not administered landiolol (group C) during the same period. Use of landiolol was decided by anesthesiologists, who declined to use landiolol in patients who had hemodynamic instability. Those with a systolic blood pressure (SBP) \<80 mmHg were treated with landiolol at the discretion of the anesthesiologist.

The administration of landiolol was initiated at 2 μg/kg/min (γ) after completion of the distal anastomoses. It was increased in increments of γ, titrating to a target heart rate (HR) of 80 beats/min. The minimum dose was γ, and this dose was used during the intensive care unit (ICU) stay. The criterion for discontinuation of treatment was excessive reduction in systolic blood pressure (SBP) to \<80 mmHg or in heart rate (HR) to less than 60 beats/min that did not improve with inotropic agents.

Patients were continuously monitored using alarm-triggered bedside monitors during the first 48 h after surgery and continuous Holter monitoring with three-lead, alarm-triggered telemetry systems until postoperative day 7. Postoperative AF was observed via continuous electrocardiographic monitoring or a 12-lead electrocardiogram. AF was defined as an absence of P waves before QRS complexes that continued for 30 min and the presence of an irregular heartbeat. Persistence of electrocardiographic changes for \<30 min but requiring treatment, such as further administration of antiarrhythmic drugs and countershock, was also considered postoperative AF.

Univariate analysis of factors associated with the occurrence of postoperative AF was performed using a logistic regression model. IBM SPSS Statistics for Windows, Version 19.0 (IBM Corp., Armonk, NY, USA), was used for all analyses.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 and 2008. Informed consent was obtained from all patients for being included in the study.

Results {#Sec3}
=======

Patients' preoperative characteristics are listed in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Mean age was 69.46 ± 1.56 years in group L and 67.25 ± 0.97 years in group C, with females constituting 19.5% and 16.0% of patients, respectively. There were no significant differences in preoperative characteristics or intraoperative data, or with respect to the number of diseased vessels, left ventricular ejection fraction or European System for Cardiac Operative Risk Evaluation (EuroSCORE) \[[@CR11]\]. Intraoperative variables are listed in Table [3](#Tab3){ref-type="table"}. No significant between-group differences were observed in operative duration or number of distal coronary anastomoses. Hospital death was not observed in either group (Tables [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}). The incidences of major complications, except postoperative AF, were equivalent in the two groups; the incidence of postoperative AF was significantly lower in group L than in group C (12.2% versus 30.67%, *P* = 0.0263).Table 1Preoperative patient characteristicsGroup C (*n* = 75)Group L (*n* = 41)*P* valueMean age (years)67.25 ± 0.9769.46 ± 1.560.2090Age \>70 years (*n*)36 (48.0%)20 (48.8%)0.9336Female sex12 (16.0%)8 (19.5%)0.6357Body surface area (m^2^)1.65 ± 0.021.61 ± 0.030.2741OMI15 (20.0%)6 (14.6%)0.4774LVEF (%)58.27 ± 1.6955.72 ± 2.370.3768EF \< 40% (*n*)9 (12.0%)9 (22.0%)0.1598Number of diseased vessels2.76 ± 0.052.81 ± 0.090.6642LMT \>50%23 (30.7%)16 (39.0%)0.3667β-Blocker14 (18.7%)7 (17.1%)0.8331Data presented as mean ± standard deviation unless otherwise indicated*C* control, *EF* ejection fraction, *L* landiolol, *LMT* left main trunk, *LVEF* left ventricular ejection fraction, *OMI* old myocardial infarctionTable 2Preoperative patient characteristicsGroup C (*n* = 75)Group L (*n* = 41)*P* valueHypertension59 (78.70%)37 (90.20%)0.1116Hyperlipidemia42 (56.00%)24 (58.50%)0.7924Diabetes mellitus47 (62.70%)27 (65.90%)0.7355Peripheral arterial disease7 (9.33%)4 (9.75%)0.9414Chronic renal failure (creatinine \>1.5)14 (18.70%)5 (12.20%)0.3723EuroSCORE (standard)4.69 ± 0.354.12 ± 0.430.8587Data presented as *n* (%) or mean ± standard deviation*C* control, *EuroSCORE* European System for Cardiac Operative Risk Evaluation, *L* landiololTable 3Intraoperative variablesGroup C (*n* = 75)Group L (*n* = 41)*P* valueOperative duration (h)5.93 ± 0.115.76 ± 0.190.4510Scheduled IABP (*n*)11 (14.7%)11 (26.8%)0.1121Number of distal anastomoses4.23 ± 0.123.81 ± 0.250.1111LITA73 (97.3%)41 (100.0%)0.2956RITA23 (30.7%)12 (29.3%)0.8767RA37 (49.3%)18 (43.9%)0.5794SVG67 (89.3%)39 (95.1%)0.2924Dopamine (μg/kg/min)5.19 ± 0.215.18 ± 0.260.9732Data presented as *n* (%) or mean ± standard deviation*C* control, *IABP* intra-aortic balloon pump, *L* landiolol, *LITA* left internal thoracic artery, *RA* renal artery, *RITA* right internal thoracic artery, *SVG* saphenous vein graftTable 4Postoperative variablesGroup C (*n* = 75)Group L (*n* = 41)*P* valueIntensive care unit stay (days)2.57 ± 0.272.83 ± 0.380.5855Intubation time (h)22.1 ± 3.8118.4 ± 2.520.5140Hospital stay (days)18.8 ± 0.8418.0 ± 0.980.6145Data presented as mean ± standard deviation*C* control, *L* landiololTable 5Perioperative variablesGroup C (*n* = 75)Group L (*n* = 41)*P* valueAtrial fibrillation23 (30.67%)5 (12.20%)0.0263Perioperative stroke1 (13.30%)0 (0.00%)0.462130-day mortality0 (0.00%)0 (0.00%)--*C* control, *L* landiolol

Measurements of SBP, HR, cardiac index (CI), and systemic vascular resistance index (SVRI) for both groups intraoperatively and at postoperative day 1 are shown Fig. [1](#Fig1){ref-type="fig"}. There were no between-group differences in hemodynamic parameters at any time point. However, SBP significantly increased in both groups, and significant decreases were seen in HR (*P* \< 0.05) and CI (*P* \< 0.05) in group L. We used preoperative and postoperative oral medication (β-blocker), sex, age, body surface area, and left ventricular ejection fraction as variables in our analysis, and significant differences were associated with the administration of landiolol (*P* = 0.026), as listed in Table [6](#Tab6){ref-type="table"}.Fig. 1Measurements of systolic blood pressure, heart rate, cardiac index and systemic vascular resistance index for both groups intraoperatively and at postoperative day 1. *CI* cardiac index, *HR* heart rate, *ICU* intensive care unit, *OPE* intraoperative, *POD1* postoperative day 1, *SBP* systolic blood pressure, *SVRI* systemic vascular resistance indexTable 6Relationships of various factors to postoperative atrial fibrillationAF+ (*n* = 28)AF− (*n* = 88)*P* valueMean age68.38 ± 1.4567.93 ± 0.990.8235Age \>70 years14 (53.60%)42 (47.70%)0.5938Female sex4 (14.30%)14 (15.90%)0.8380Body surface area1.64 ± 0.031.65 ± 0.020.7177OMI3 (10.70%)18 (20.50%)0.2474LVEF (%)58.91 ± 2.8756.64 ± 1.570.3241Number of disease vessels2.73 ± 0.102.79 ± 0.060.6237Landiolol use5 (17.90%)36 (40.90%)0.0263β-Blocker5 (17.90%)16 (18.20%)0.9693Data presented as *n* (%) or mean ± standard deviation*AF*+ patients with postoperative atrial fibrillation, *AF*− patients with no postoperative atrial fibrillation, *LVEF* left ventricular ejection fraction, *OMI* old myocardial infarction

Postoperative AF occurred in 12.2% of patients in group L and 30.7% of patients in group C (log rank *P* = 0.0463) (Fig. [2](#Fig2){ref-type="fig"}); a difference significantly associated with the use of landiolol.Fig. 2Freedom from postoperative atrial fibrillation. *C* control, *L* landiolol

Discussion {#Sec4}
==========

Landiolol is a novel ultrashort-acting β-blocker that has a plasma half-life of 4 min \[[@CR12]\]. In a recent randomized controlled study, Sezai et al. \[[@CR13]\] reported that landiolol administration significantly reduced heart rate and the occurrence of AF in post-cardiac surgery patients without a significant change in blood pressure. Another prospective multi-center randomized study of landiolol in adult patients (JL-KNIGHT) \[[@CR14]\] was recently undertaken in Japan. This drug has been widely used in Japan and has higher β1 selectivity than any currently available β-blocker, but has neither intrinsic sympathomimetic activity nor significant membrane-stabilizing activity \[[@CR15]--[@CR18]\]. However, until now little information on the efficacy of intraoperative landiolol use in patients undergoing cardiac surgery has been available.

AF is one of the most frequent complications following cardiac surgery, occurring in 25% to 40% of cases \[[@CR1]\]. Postoperative AF has been shown to result from thromboembolism, and it leads to extended ICU and hospital stays and increased medical costs \[[@CR2]--[@CR5]\]. Moreover, tachyarrhythmia, of which the most common type is AF, increases myocardial oxygen consumption \[[@CR19]\]. Previous studies have reported that postoperative AF increases the incidence of postoperative pneumonia, myocardial infarction and heart failure and, consequently, mortality. It is also considered a risk factor for myocardial ischemia because a shortened left ventricular diastolic time decreases coronary artery blood flow \[[@CR20]\]. The utility of landiolol in preventing postoperative AF has been widely reported. Previous studies using β-blockers or amiodarone have reported significant reductions in postoperative AF compared with placebo; however, the incidence varied widely, from 3% to 34% \[[@CR21], [@CR22]\].

In this study, among the factors previously considered risk factors for postoperative AF (including advanced age, male sex, body surface area and β-blocker use), we found age and landiolol administration to be inhibitory. Postoperative AF was observed in only five patients in group L. Peak incidence of postoperative AF occurred in the first 2--3 days following CABG. We note, however, that not only was AF significantly inhibited during the administration of landiolol, but its occurrence within 1 week of surgery was also reduced. Because the half-life of the drug is short, the reason for its effect after discontinuation is unknown, as is the mechanism for inhibiting AF within 1 week, but we believe that the ability of the drug to decrease HR during the acute period and consequently stabilize hemodynamics leads to the inhibition of postoperative AF.

We believe landiolol to have a stabilizing effect during the perioperative period. However, in the present study, the safety of landiolol and the suitability of the current method of administration were studied only with regard to intraoperative administration. We believe this β-blocker can be safe and effective if appropriate administration methods are devised. It is necessary, however, to increase the number of cases and to study outcomes during the follow-up period.

Limitations {#Sec5}
===========

There are some limitations associated with this study. First, our study was retrospective in nature and carried out at a single institution. The number of patients was small, because only isolated coronary surgery cases were selected. Because this drug has a very short half-life, an administration method that minimizes the occurrence of side effects should be developed. An anesthesiologist declined to use when hemodynamic instability. The selection criterion for patients to be treated with landiolol is the choice of anesthesiologist, and was not recorded due to the study being retrospective. We consider landiolol to be safe when it is initiated at 2 μg/kg/min intraoperatively, and we experienced no major complications with this method of administration. It will be important to carry out multi-center randomized controlled trials evaluating this rate of administration method in the future.

Conclusion {#Sec6}
==========

Landiolol, an ultrashort-acting β1-selective blocker, has a preventive effect on the development of AF after CABG surgery and may achieve successful perioperative management of patients. To further these findings, we plan to conduct a randomized prospective study to investigate the inhibitory effects of intraoperative study landiolol on postoperative AF in patients who have undergone off-pump CABG.
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